Reyes J M, Okazaki N, Yoshino M, Yoshida T
Jpn J Clin Oncol. 1984 Mar;14(1):41-7.
Twenty-four eligible and evaluable patients with measurable liver metastases from gastric cancer were treated with oral or rectal Tegafur. Objective responses were seen in 8 of the patients (33.3%), lasting between 1.5 and 15 months. The median survival period was 10 months for the responders and 2.6 months for non-responders. No complete response was observed. The survival of responders was significantly longer than that of non-responders (p less than 0.01). Toxicity was mild and consisted principally of gastrointestinal and hematological side effects. No central nervous system toxicity was seen.
24例患有可测量胃癌肝转移的合格且可评估患者接受了口服或直肠替加氟治疗。8例患者（33.3%）出现客观缓解，持续时间为1.5至15个月。缓解者的中位生存期为10个月，未缓解者为2.6个月。未观察到完全缓解。缓解者的生存期明显长于未缓解者（p<0.01）。毒性较轻，主要包括胃肠道和血液学副作用。未观察到中枢神经系统毒性。
